First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: Molecular characteristics in relation to response

Neuro-Oncology

Volumn 13, Issue 2, 2011, Pages 235-241

  Taal, Walter ^a   Dubbink, Hendrikus J ^b   Zonnenberg, Chris B L ^c,g   Zonnenberg, Bernard A ^d   Postma, Tjeerd J ^c   Gijtenbeek, Johanna M M ^e   Boogerd, Willem ^f   Groenendijk, Floris H ^b,h   Kros, Johan M ^b   Kouwenhoven, Mathilde C M ^a   Van Marion, Ronald ^b   Van Heuvel, Irene ^a   Van Der Holt, Bronno ^a   Bromberg, Jacoline E C ^a   Smitt, Peter A E Sillevis ^a   Dinjens, Winand N M ^b   Van Den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g Infection and Immunology   (Netherlands)

^h MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

19q; 1p; Brain tumors; Chemotherapy; Glioma; IDH1; IDH2; Low grade astrocytoma; MGMT; Temozolomide; TP53; Trisomy 7

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 7; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROMOTER REGION; STATISTICAL SIGNIFICANCE; TRISOMY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DACARBAZINE; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; TRISOMY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79951838572     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq177     Document Type: Article

References (34)

1. Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007;69:1366-1373. (Pubitemid 47482451)
2. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338-1345.
3. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549-556. (Pubitemid 26404297)
4. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligoden-droglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-990. (Pubitemid 41323034)
5. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722-1726. (Pubitemid 38029042)
6. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolo-mide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646-651. (Pubitemid 46621898)
7. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. 2002;103:267-275. (Pubitemid 36075328)
8. Ishii N, Tada M, Hamou MF, et al. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene. 1999;18:5870-5878. (Pubitemid 29520443)
9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
10. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009;73:1792-1795.
11. Wessels PH, Twijnstra A, Kessels AG, et al. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer. 2002;33:279-284. (Pubitemid 34130934)
12. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
13. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;21:2525-2528. (Pubitemid 46606334)
14. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
15. van der Sijp JR, van Meerbeeck JP, Maat AP, et al. Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J Clin Oncol. 2002;20:1105-1114. (Pubitemid 34141856)
16. Jeuken JW, Cornelissen SJ, Vriezen M, et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007;87:1055-1065. (Pubitemid 47429190)
17. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27:5881-5886.
18. Groenendijk FH, Taal W, Dubbink HJ, et al. MGMT promoter hyper-methylation is a frequent, early and consistent event in astrocytoma progression and not correlated with TP53 mutation. [published online ahead of print July 1, 2010]. J Neurooncol. doi: 10.1007/s11060-010-0274-x.
19. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42:2499-2503 (Pubitemid 44468379)
20. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-Oncology 2009;11:737-746.
21. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oli-goastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-2771 (Pubitemid 29415233)
22. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007;26:186-197. (Pubitemid 46095730)
23. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96:766-776.
24. Naumann SC, Roos WP, Jost E, et al. Temozolomide-and fotemustine-induced apoptosis in human malignant melanoma cells response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009;100:322-333
25. Watanabe T, Katayama Y, Yoshino A, et al. Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol. 2007;17:5-10.
26. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22:1715-1719. (Pubitemid 32952152)
27. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006;60:740-743. (Pubitemid 46048490)
28. Nakasu S, Fukami T, Jito J, Matsuda M. Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol. 2007;68:603-608. Discussion 608-609. (Pubitemid 350160837)
29. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003;13:176-184. (Pubitemid 36460818)
30. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligoden-drogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer. 2006;106:1759-1765.
31. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendro-glial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
32. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
33. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarba-zine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-5880.
34. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.